RECEIVED CENTRAL FAX CENTER FEB 2 7 2006

Attorney Docket No.: 10181.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ness et al.

Confirmation No: 6691

Serial No.: 10/736,997

Group Art Unit: 1652

Filed: December 15, 2003

Examiner: W. Moore

For: Subtilisin Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

Amendment Fee Transmittal (in duplicate)

2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner W. Moore, fax number (571)273-8300 .

Respectfully submitted,

Date: February 27, 2006

Julie Tabarovsky

Moyozymes North America, Inq

500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097

RECEIVED CENTRAL FAX CENTER

FEB 2 7 2006

Attorney Docket No.: 10181.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ness et al.

Confirmation No: 6691

Serial No.: 10/736,997

Group Art Unit: 1652

Filed: December 15, 2003

Examiner: W. Moore

For: Subtilisin Variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed August 25, 2005.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from November 25, 2005 to February 25, 2006. The required fee for the extension is estimated to be \$1,020.

The fee for claims has been calculated as shown below:

Total: $38 - 20 = 18 \times 50 = 900

Independent: $1 - 3 = 0 \times 200 = 0

Total additional fee for claims required is \$900.

Please charge the required extension and claims fees, estimated to be \$1,920, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 27, 2006

Elias J. Lambins, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

New York, NY 10110 (212) 840-0097

RECEIVED **CENTRAL FAX GENTER**

FEB 2 7 2006

Attorney Docket No.: 10181.210-US

12128400221

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ness et al.

Confirmation No: 6691

Serial No.: 10/736,997

Group Art Unit: 1652

Filed: December 15, 2003

Examiner: W. Moore

For: Subtilisin Variants

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed August 25, 2005.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from November 25, 2005 to February 25, 2006. The required fee for the extension is estimated to be \$1,020.

The fee for claims has been calculated as shown below:

Total: $38 - 20 = 18 \times 50 = 900

Independent: $1 - 3 = 0 \times 200 = 0

Total additional fee for claims required is \$900.

Please charge the required extension and claims fees, estimated to be \$1,920, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 27, 2006

Elias J. Lambiris, Reg. No. 33,728 Novozymes Worth America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097

Attorney Docket No.: 10181.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ness et al.

Confirmation No: 6691

Serial No.: 10/736,997

Group Art Unit: 1652

Filed: December 15, 2003

Examiner: W. Moore

For: Subtilisin Variants

AMENDMENT UNDER 37 C.F.R. 1.111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed August 25, 2005, please amend the above-identified application as follows:

Amendments to the specification begin on page 2 of this document.

Amendments to the claims are reflected in the listing of claims, which begins on page 3 of this document.

Remarks and arguments begin on page 7 of this document.